ViCardia Therapeutics Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
ViCardia Therapeutics Inc., a privately held company founded in 2017, based in San Francisco, is entering Phase 2 with GP531, a potent, long-lasting infusion therapy that treats mitochondrial dysfunction in acute heart failure.

ViCardia is led by a highly experienced management team, board of directors and board of scientific advisors with extensive experience in treating chronic and acute heart failure and conducting cardiovascular research.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
GP531
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
President & CEO
ViCardia Therapeutics, Inc.